公开(公告)号：EP2542261B1

公开(公告)日：2016-07-06

申请号：EP11705617.6

申请日：2011-03-01

申请人： Glaxo Group Limited

发明人： BHINDER, Tejinder, Kaur ,  FORD, Susannah, Karen ,  GERMASCHEWSKI, Volker ,  LEWIS, Alan, Peter ,  PEPYS, Mark, Brian

IPC分类号： A61K39/00 ,  C07K16/18

CPC分类号： C07K16/18 ,  A61K2039/505 ,  A61K2039/545 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/54 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/92

公开(公告)号：EP2542261A1

公开(公告)日：2013-01-09

申请号：EP11705617.6

申请日：2011-03-01

申请人： Glaxo Group Limited

发明人： BHINDER, Tejinder, Kaur ,  FORD, Susannah, Karen ,  GERMASCHEWSKI, Volker ,  LEWIS, Alan, Peter ,  PEPYS, Mark, Brian

IPC分类号： A61K39/395 ,  A61P25/28 ,  C07K16/18

CPC分类号： C07K16/18 ,  A61K2039/505 ,  A61K2039/545 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/54 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/92

摘要： The present invention relates to antigen binding proteins, such as antibodies, which bind to serum amyloid P component (SAP), polynucleotides encoding such antigen binding proteins, pharmaceutical compositions comprising said antigen binding proteins and methods of manufacture. The present invention also concerns the use of such antigen binding proteins in the treatment or prophylaxis of diseases associated with amyloid deposition including systemic amyloidosis, local amyloidosis, Alzheimer's disease, and type 2 diabetes.